These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1053378)

  • 41. Brief Update on Dermatologic Uses of Methotrexate.
    Shah RA; Nwannunu CE; Limmer AL; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Nov; 24(6):5-8. PubMed ID: 31801013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
    Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept.
    Cusano F; Iannazzone SS; Riccio G; Piccirillo F
    Eur J Dermatol; 2010; 20(4):520. PubMed ID: 20403800
    [No Abstract]   [Full Text] [Related]  

  • 44. Dermatologic applications of cyclosporine.
    Biren CA; Barr RJ
    Arch Dermatol; 1986 Sep; 122(9):1028-32. PubMed ID: 3527076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update.
    Roujeau JC; Ingen-Housz-Oro S; Leroux C; Joly P
    G Ital Dermatol Venereol; 2009 Aug; 144(4):333-8. PubMed ID: 19755939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of pemphigus and pemphigoids.
    López-Jornet P; Bermejo-Fenoll A
    Med Oral Patol Oral Cir Bucal; 2005; 10(5):410-1. PubMed ID: 16264376
    [No Abstract]   [Full Text] [Related]  

  • 47. WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
    Choy EH; Hoogendijk JE; Lecky B; Winer JB; Gordon P
    Cochrane Database Syst Rev; 2009 Oct; (4):CD003643. PubMed ID: 19821312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
    Choy EH; Hoogendijk JE; Lecky B; Winer JB
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003643. PubMed ID: 16034905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppressive therapy for autoimmune bullous diseases.
    Meurer M
    Clin Dermatol; 2012; 30(1):78-83. PubMed ID: 22137230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Photochemotherapy: dermatologic uses.
    Roenigk HH
    South Med J; 1978 Dec; 71(12):1489-92. PubMed ID: 725627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Autoimmune bullous skin disorders].
    Hertl M; Niedermeier A; Borradori L
    Ther Umsch; 2010 Sep; 67(9):465-82. PubMed ID: 20806175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of bullous pemphigoid: recommendations for immunomodulatory treatments.
    Kirtschig G; Khumalo NP
    Am J Clin Dermatol; 2004; 5(5):319-26. PubMed ID: 15554733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Monitoring of sE-selectin serum levels in three different dermatoses].
    D'Auria L; Bonifati C; Mussi A; Ameglio F
    Clin Ter; 1998; 149(921):49-52. PubMed ID: 9621489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of B cells in immune-mediated dermatoses.
    Wang WM; Guo L; Jin HZ
    Mol Immunol; 2020 Oct; 126():95-100. PubMed ID: 32795664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.
    Yamauchi PS; Lowe NJ; Gindi V
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S121-2. PubMed ID: 16488323
    [No Abstract]   [Full Text] [Related]  

  • 56. Azathioprine: its uses in dermatology.
    Chavez-Alvarez S; Herz-Ruelas M; Villarreal-Martinez A; Ocampo-Candiani J; Garza-Garza R; Gomez-Flores M
    An Bras Dermatol; 2020; 95(6):731-736. PubMed ID: 33250113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide.
    Itoh T; Hosokawa H; Shirai Y; Horio T
    Br J Dermatol; 1996 May; 134(5):931-3. PubMed ID: 8736339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid.
    Shi CR; Otto TS; Thompson LL; Chang MS; Reynolds KL; Chen ST
    Eur J Cancer; 2021 Dec; 159():34-37. PubMed ID: 34731747
    [No Abstract]   [Full Text] [Related]  

  • 59. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs.
    White SD; Rosychuk RA; Reinke SI; Paradis M
    J Am Vet Med Assoc; 1992 May; 200(10):1497-500. PubMed ID: 1535346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.